Alvotech and Advanz Pharma have submitted a European regulatory application for AVT29, a proposed biosimilar to high-dose ...

Innovation in therapeutics has a lot on the horizon, he said, but all of those drugs and innovations can only be delivered by ...

At AAO 2026, Michael T. Yen, MD, explained how at-home subcutaneous elegrobart could ease treatment burden in thyroid eye ...

In addition to the results, Roche also announced that the US Food and Drug Administration (FDA) has accepted the company’s ...

Ehsan Rahimy, MD, says most PRIMA serious adverse events occurred early, while vision gains held through 36 months.

Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual ...

Koreishi, MD, explains why inflammation control and planning are key to cataract surgery for patients with uveitis.

Liza M. Cohen, MD, explains when to use CT vs MRI in thyroid eye disease and why to review images yourself.

The US Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee will meet October 30, 2026, to ...

Vaidehi Dedania, MD, shared what the first whole eye transplant revealed about reperfusion, retinal cells, and sight. Dedania ...

David F. Chang, MD, explained how offering complementary refractive IOLs reduces patient anxiety and indecision.

The course is designed for comprehensive and pediatric ophthalmologists and optometrists, who often see patients with new ...